Trimethoprim, Sulfamethoxazole Drug Combination
"Trimethoprim, Sulfamethoxazole Drug Combination" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.
| Descriptor ID |
D015662
|
| MeSH Number(s) |
D02.065.884.725.867.500 D02.092.146.807.867.500 D02.886.590.700.725.867.500 D03.383.742.906.500 D26.310.875
|
| Concept/Terms |
Trimethoprim, Sulfamethoxazole Drug Combination- Trimethoprim, Sulfamethoxazole Drug Combination
- Centrin
- Cotrimoxazole
- Eslectin
- Insozalin
- TMP-SMX
- Trimethoprim-Sulfamethoxazole
- Trimethoprim Sulfamethoxazole
- Sulfamethoxazole-Trimethoprim Combination
- Sulfamethoxazole Trimethoprim Combination
- Trimethoprim-Sulfamethoxazole Combination
- Trimethoprim Sulfamethoxazole Combination
- Trimezole
- Co-Trimoxazole
- Co Trimoxazole
- TMP SMX
- Centran
- Trimedin
|
Below are MeSH descriptors whose meaning is more general than "Trimethoprim, Sulfamethoxazole Drug Combination".
Below are MeSH descriptors whose meaning is more specific than "Trimethoprim, Sulfamethoxazole Drug Combination".
This graph shows the total number of publications written about "Trimethoprim, Sulfamethoxazole Drug Combination" by people in this website by year, and whether "Trimethoprim, Sulfamethoxazole Drug Combination" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Trimethoprim, Sulfamethoxazole Drug Combination" by people in Profiles.
-
Cao B, Robinson JE, Winget M, Hunt MH, Carlson R, Hogan SL, Derebail VK, Thorpe CT. Infection prophylaxis among patients with antineutrophil cytoplasmic antibody (ANCA) vasculitis: a scoping review. Clin Rheumatol. 2024 Sep; 43(9):2765-2781.
-
Sahu KK, Mishra AK, Lal A, Siddiqui AD, George SV. Methemoglobinemia: a challenge while managing pneumocystis jirovecii pneumonia. N Z Med J. 2020 05 08; 133(1514):88-89.
-
Gkrouzman E, Chirch L, Lakshminarayanan S. Drug-Induced Sweet Syndrome in a Man With Sarcoidosis: Are There Any Common Mechanisms of Pathogenesis? J Clin Rheumatol. 2019 10; 25(7):e122-e126.
-
Morrill HJ, Morton JB, Caffrey AR, Jiang L, Dosa D, Mermel LA, LaPlante KL. Antimicrobial Resistance of Escherichia coli Urinary Isolates in the Veterans Affairs Health Care System. Antimicrob Agents Chemother. 2017 05; 61(5).
-
Lally DR, Sharma DK, Shields CL, Malloy BC, Garg SJ. Pulmonary nocardiosis initially manifesting as endogenous endophthalmitis. Can J Ophthalmol. 2014 Apr; 49(2):e59-62.
-
Silverberg JI, Votava HJ, Smith BL. Antiphospholipid antibody syndrome secondary to trimethoprim/sulfamethoxazole. J Drugs Dermatol. 2012 Sep; 11(9):1117-8.
-
Gabardi S, Millen P, Hurwitz S, Martin S, Roberts K, Chandraker A. Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation. Clin Transplant. 2012 May-Jun; 26(3):E184-90.
-
Leming MK, Breyer MJ. Renal failure in a patient with postpolio syndrome and a normal creatinine level. Am J Emerg Med. 2012 Jan; 30(1):247.e1-3.
-
Rotjanapan P, Dosa D. Asymptomatic versus symptomatic urinary tract infections in long-term-care-facility residents. Med Health R I. 2009 Nov; 92(11):377-9.
-
Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Kalish LA, Finberg R. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol. 1995 Jan; 13(1):239-50.